Across TCGA pan-cancer cohorts, ERC2 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ERC2 data layer compared with 23 for mass-spec protein and 6 for mutation status.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ERC2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ERC2 expression acts as an unfavorable survival marker.
UCEC are the cancer types where ERC2 mass-spec protein most reproducibly stratifies survival.